Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Changsong, Gong, Jifang, Li, Jian, Liu, Dan, Qin, Yanru, Ge, Sai, Zhang, Miao, Peng, Zhi, Zhou, Jun, Cao, Yanshuo, Zhang, Xiaotian, Lu, Zhihao, Lu, Ming, Yuan, Jiajia, Wang, Zhenghang, Wang, Yakun, Peng, Xiaohui, Gao, Huiping, Liu, Zhen, Wang, Huamao, Yuan, Daijing, Xiao, Jun, Ma, Hong, Wang, Wei, Li, Zonghai, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205778/
https://www.ncbi.nlm.nih.gov/pubmed/35534566
http://dx.doi.org/10.1038/s41591-022-01800-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205778/
https://www.ncbi.nlm.nih.gov/pubmed/35534566
http://dx.doi.org/10.1038/s41591-022-01800-8

Ejemplares similares